산모 보건 치료 시장 - 규모, 점유율, 성장률, 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of maternal health therapeutics Market

The global maternal health therapeutics market demonstrated steady growth in 2025, supported by rising government focus on maternal healthcare, increasing investments in women's health programs, and a growing burden of pregnancy-related complications. According to the report, the global maternal health therapeutics market size was valued at USD 4.6 billion in 2025 and is projected to grow from USD 4.91 billion in 2026 to USD 8.84 billion by 2034, registering a CAGR of 7.63% during the forecast period. North America dominated the market with a 42.32% share in 2025, owing to strong healthcare infrastructure, higher institutional births, and greater access to advanced therapeutics.

Maternal health therapeutics include drugs used across preconception, pregnancy, labor & delivery, and postpartum stages to manage complications such as preeclampsia, gestational diabetes, postpartum hemorrhage, and postpartum depression. The rising prevalence of lifestyle-related disorders, delayed pregnancies, and increasing birth complications is driving demand for specialized therapeutic solutions. Additionally, several pharmaceutical companies are strengthening their pipelines to address unmet needs in maternal care.

Market Dynamics

Market Drivers

The rising number of births globally remains a major driver of the maternal health therapeutics market. An increasing maternal population directly expands the risk pool for pregnancy-related complications, driving demand for uterotonics, antihypertensives, insulin, antibiotics, and antidepressants. Growing institutional deliveries and improved access to healthcare services are further supporting market growth.

According to UNICEF (2023), approximately 132.11 billion births were reported globally, highlighting the expanding demand for maternal healthcare services and therapeutics.

Market Restraints

A key restraint is the lack of pregnancy-specific therapeutics. Many drugs used for maternal complications are off-label treatments initially developed for the general population. This reliance raises concerns related to safety, dosage optimization, and long-term outcomes for pregnant and postpartum women.

In December 2023, the World Health Organization (WHO) reported that at least 40.0 million women annually experience long-term health problems caused by childbirth, underscoring the existing treatment gap despite a high disease burden.

Market Opportunities

Innovation in postpartum care offers a major growth opportunity. Postpartum conditions such as hemorrhage, depression, and infections contribute significantly to maternal morbidity and mortality but remain underserved.

In December 2023, Biogen Inc., in collaboration with Sage Therapeutics, launched ZURZUVAE for the treatment of postpartum depression in adults in the U.S., highlighting the growing focus on postpartum therapeutics.

Market Challenges

Limited access to maternal health therapeutics in low-income countries poses a critical challenge. Weak supply chains, inconsistent availability, and poor healthcare infrastructure restrict effective drug distribution.

According to UNICEF (2024), countries such as South Sudan, Chad, and Somalia continue to face inadequate healthcare facilities, limiting access to essential maternal medicines despite growing demand.

Maternal Health Therapeutics Market Trends

An important trend shaping the market is increasing government support for maternal healthcare. Governments are prioritizing maternal safety through national programs, funding initiatives, and policy reforms.

In February 2024, the U.S. Department of Health and Human Services (HHS) launched the Secretary's Postpartum Maternal Health Collaborative to address postpartum mortality, reflecting rising policy-level commitment.

Segmentation Analysis

By drug type, fertility drugs are projected to dominate with a 33.39% share in 2026, while hormonal therapies hold a significant share due to high utilization of uterotonics for postpartum hemorrhage. By application, gestational diabetes is projected to lead with a 27.09% share in 2026, while postpartum hemorrhage accounted for 15.7% share in 2025. By phase, preconception is expected to account for 42.25% share in 2026, while the postpartum segment is anticipated to witness strong growth. By route of administration, oral therapies are projected to hold 55.10% share in 2026. By distribution channel, hospital pharmacies dominated with a 50.8% share in 2025, supported by their role in managing high-risk maternal conditions.

Regional Outlook

North America led the market with USD 1.95 billion in 2025 and USD 2.08 billion in 2026, driven by rising cases of postpartum depression, preeclampsia, and gestational diabetes. Europe reached USD 1.19 billion in 2025, supported by increasing awareness and healthcare investments. Asia Pacific followed with USD 1.14 billion in 2025, while Latin America and the Middle East & Africa recorded USD 0.19 billion and USD 0.06 billion, respectively.

Competitive Landscape

The market is semi-consolidated, with key players such as Johnson & Johnson, Novartis AG, Pfizer Inc., Biogen, and Merck & Co., Inc. focusing on collaborations, R&D investments, and strategic initiatives to expand their maternal health portfolios.

Conclusion

The global maternal health therapeutics market was valued at USD 4.6 billion in 2025 and is expected to grow from USD 4.91 billion in 2026 to USD 8.84 billion by 2034, driven by rising birth rates, increasing maternal complications, strong government support, and expanding pharmaceutical pipelines. North America maintained market leadership, while Europe and Asia Pacific demonstrated significant growth potential. Despite challenges such as limited access in low-income countries and reliance on off-label therapies, continued innovation in postpartum care, supportive government initiatives, and growing awareness of maternal health are expected to sustain market expansion through 2034.

Segmentation By Drug Type, Application, Phase, Route of Administration, Distribution Channel, and Region

By Drug Type * Hormonal Therapies

• GnRH Modulators
• Pain & Symptom Management
• Metabolic Drugs
• Fertility Drugs
• Others

By Application * Preeclampsia & Gestational Hypertension

• Gestational Diabetes
• Postpartum Hemorrhage
• Postpartum Depression
• Hyperemesis Gravidarum
• Alloimmune Thrombocytopenia (FNAIT)
• Postpartum Endometritis
• Others

By Phase * Preconception

• Prenatal
• Labor & delivery
• Postnatal/ Postpartum

By Route of Administration * Oral

• Parenteral

By Distribution Channel * Hospital Pharmacies

• Drug Stores & Retail Pharmacies
• Online Pharmacies

By Geography * North America (By Drug Type, Application, Phase, Route of Administration, Distribution Channel, and Country)

• U.S.
• Canada
• Europe (By Drug Type, Application, Phase, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Drug Type, Application, Phase, Route of Administration, Distribution Channel, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Drug Type, Application, Phase, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Drug Type, Application, Phase, Route of Administration, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Regulatory Scenarios, By Key Countries/Regions
• 4.2. Pipeline Analysis, By Key Players
• 4.3. Epidemiology- Key Diseases, By Key Countries/ Regions
• 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

5. Global Maternal Health Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug Type
  • 5.1.1. Hormonal Therapies
  • 5.1.2. GnRH Modulators
  • 5.1.3. Pain & Symptom Management
  • 5.1.4. Metabolic Drugs
  • 5.1.5. Fertility Drugs
  • 5.1.6. Others
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Preeclampsia & Gestational Hypertension
  • 5.2.2. Gestational Diabetes
  • 5.2.3. Postpartum Hemorrhage
  • 5.2.4. Postpartum Depression
  • 5.2.5. Hyperemesis Gravidarum
  • 5.2.6. Alloimmune Thrombocytopenia (FNAIT)
  • 5.2.7. Postpartum Endometritis
  • 5.2.8. Others
• 5.3. Market Analysis, Insights and Forecast - By Phase
  • 5.3.1. Preconception
  • 5.3.2. Prenatal
  • 5.3.3. Labor & Delivery
  • 5.3.4. Postnatal/ Postpartum
• 5.4. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.4.1. Oral
  • 5.4.2. Parenteral
• 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.5.1. Hospital Pharmacies
  • 5.5.2. Drug Stores & Retail Pharmacies
  • 5.5.3. Online Pharmacies
• 5.6. Market Analysis, Insights and Forecast - Region
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. Asia Pacific
  • 5.6.4. Latin America
  • 5.6.5. Middle East & Africa

6. North America Maternal Health Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug Type
  • 6.1.1. Hormonal Therapies
  • 6.1.2. GnRH Modulators
  • 6.1.3. Pain & Symptom Management
  • 6.1.4. Metabolic Drugs
  • 6.1.5. Fertility Drugs
  • 6.1.6. Others
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Preeclampsia & Gestational Hypertension
  • 6.2.2. Gestational Diabetes
  • 6.2.3. Postpartum Hemorrhage
  • 6.2.4. Postpartum Depression
  • 6.2.5. Hyperemesis Gravidarum
  • 6.2.6. Alloimmune Thrombocytopenia (FNAIT)
  • 6.2.7. Postpartum Endometritis
  • 6.2.8. Others
• 6.3. Market Analysis, Insights and Forecast - By Phase
  • 6.3.1. Preconception
  • 6.3.2. Prenatal
  • 6.3.3. Labor & delivery
  • 6.3.4. Postnatal/ Postpartum
• 6.4. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.4.1. Oral
  • 6.4.2. Parenteral
• 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.5.1. Hospital Pharmacies
  • 6.5.2. Drug Stores & Retail Pharmacies
  • 6.5.3. Online Pharmacies
• 6.6. Market Analysis, Insights and Forecast - By Country
  • 6.6.1. U.S.
  • 6.6.2. Canada

7. Europe Maternal Health Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug Type
  • 7.1.1. Hormonal Therapies
  • 7.1.2. GnRH Modulators
  • 7.1.3. Pain & Symptom Management
  • 7.1.4. Metabolic Drugs
  • 7.1.5. Fertility Drugs
  • 7.1.6. Others
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Preeclampsia & Gestational Hypertension
  • 7.2.2. Gestational Diabetes
  • 7.2.3. Postpartum Hemorrhage
  • 7.2.4. Postpartum Depression
  • 7.2.5. Hyperemesis Gravidarum
  • 7.2.6. Alloimmune Thrombocytopenia (FNAIT)
  • 7.2.7. Postpartum Endometritis
  • 7.2.8. Others
• 7.3. Market Analysis, Insights and Forecast - By Phase
  • 7.3.1. Preconception
  • 7.3.2. Prenatal
  • 7.3.3. Labor & delivery
  • 7.3.4. Postnatal/ Postpartum
• 7.4. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.4.1. Oral
  • 7.4.2. Parenteral
• 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.5.1. Hospital Pharmacies
  • 7.5.2. Drug Stores & Retail Pharmacies
  • 7.5.3. Online Pharmacies
• 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.6.1. U.K.
  • 7.6.2. Germany
  • 7.6.3. France
  • 7.6.4. Italy
  • 7.6.5. Spain
  • 7.6.6. Scandinavia
  • 7.6.7. Rest of Europe

8. Asia Pacific Maternal Health Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug Type
  • 8.1.1. Hormonal Therapies
  • 8.1.2. GnRH Modulators
  • 8.1.3. Pain & Symptom Management
  • 8.1.4. Metabolic Drugs
  • 8.1.5. Fertility Drugs
  • 8.1.6. Others
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Preeclampsia & Gestational Hypertension
  • 8.2.2. Gestational Diabetes
  • 8.2.3. Postpartum Hemorrhage
  • 8.2.4. Postpartum Depression
  • 8.2.5. Hyperemesis Gravidarum
  • 8.2.6. Alloimmune Thrombocytopenia (FNAIT)
  • 8.2.7. Postpartum Endometritis
  • 8.2.8. Others
• 8.3. Market Analysis, Insights and Forecast - By Phase
  • 8.3.1. Preconception
  • 8.3.2. Prenatal
  • 8.3.3. Labor & delivery
  • 8.3.4. Postnatal/ Postpartum
• 8.4. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.4.1. Oral
  • 8.4.2. Parenteral
• 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.5.1. Hospital Pharmacies
  • 8.5.2. Drug Stores & Retail Pharmacies
  • 8.5.3. Online Pharmacies
• 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.6.1. China
  • 8.6.2. Japan
  • 8.6.3. India
  • 8.6.4. Southeast Asia
  • 8.6.5. Australia
  • 8.6.6. Rest of Asia Pacific

9. Latin America Maternal Health Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug Type
  • 9.1.1. Hormonal Therapies
  • 9.1.2. GnRH Modulators
  • 9.1.3. Pain & Symptom Management
  • 9.1.4. Metabolic Drugs
  • 9.1.5. Fertility Drugs
  • 9.1.6. Others
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Preeclampsia & Gestational Hypertension
  • 9.2.2. Gestational Diabetes
  • 9.2.3. Postpartum Hemorrhage
  • 9.2.4. Postpartum Depression
  • 9.2.5. Hyperemesis Gravidarum
  • 9.2.6. Alloimmune Thrombocytopenia (FNAIT)
  • 9.2.7. Postpartum Endometritis
  • 9.2.8. Others
• 9.3. Market Analysis, Insights and Forecast - By Phase
  • 9.3.1. Preconception
  • 9.3.2. Prenatal
  • 9.3.3. Labor & delivery
  • 9.3.4. Postnatal/ Postpartum
• 9.4. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.4.1. Oral
  • 9.4.2. Parenteral
• 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.5.1. Hospital Pharmacies
  • 9.5.2. Drug Stores & Retail Pharmacies
  • 9.5.3. Online Pharmacies
• 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.6.1. Brazil
  • 9.6.2. Mexico
  • 9.6.3. Rest of Latin America

10. Middle East & Africa Maternal Health Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Drug Type
  • 10.1.1. Hormonal Therapies
  • 10.1.2. GnRH Modulators
  • 10.1.3. Pain & Symptom Management
  • 10.1.4. Metabolic Drugs
  • 10.1.5. Fertility Drugs
  • 10.1.6. Others
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Preeclampsia & Gestational Hypertension
  • 10.2.2. Gestational Diabetes
  • 10.2.3. Postpartum Hemorrhage
  • 10.2.4. Postpartum Depression
  • 10.2.5. Hyperemesis Gravidarum
  • 10.2.6. Alloimmune Thrombocytopenia (FNAIT)
  • 10.2.7. Postpartum Endometritis
  • 10.2.8. Others
• 10.3. Market Analysis, Insights and Forecast - By Phase
  • 10.3.1. Preconception
  • 10.3.2. Prenatal
  • 10.3.3. Labor & delivery
  • 10.3.4. Postnatal/ Postpartum
• 10.4. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.4.1. Oral
  • 10.4.2. Parenteral
• 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.5.1. Hospital Pharmacies
  • 10.5.2. Drug Stores & Retail Pharmacies
  • 10.5.3. Online Pharmacies
• 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.6.1. GCC
  • 10.6.2. South Africa
  • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
  • 11.2.1. Novartis AG
  • 11.2.2. Johnson & Johnson
  • 11.2.3. Shionogi & Co., Ltd.
  • 11.2.4. Bayer AG (Germany)
  • 11.2.5. Bristol-Myers Squibb Company
  • 11.2.6. Biogen
  • 11.2.7. Pfizer Inc.
  • 11.2.8. Merck & Co., Inc.,